Clinical Trial Update: Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating nilotinib for newly diagnosed chronic myeloid leukemia in the accelerated phase has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Tasigna (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myeloid Leukemia (CML) | Phase 4 | Status: WITHDRAWN